Published in J Natl Cancer Inst on January 27, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood (2016) 1.05
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol (2017) 0.92
De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome. Am J Hum Genet (2017) 0.75
Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes Control (2017) 0.75
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics (2010) 52.01
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer Inst (2013) 3.15
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66
Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat (2007) 1.33
The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet (2014) 1.21
RE: PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer Inst (2014) 1.11
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol (2013) 1.03
Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer (2012) 0.92
Molecular wanderings through the DNA damage response and risk for ovarian cancer. J Natl Cancer Inst (2013) 0.81
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Whole-genome characterization of chemoresistant ovarian cancer. Nature (2015) 3.06
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol (2011) 2.64
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst (2014) 2.40
Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer (2008) 2.14
Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Gynecol Oncol (2013) 2.11
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2007) 1.92
Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer (2008) 1.82
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res (2011) 1.79
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J Natl Cancer Inst (2015) 1.70
High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer (2007) 1.65
LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res (2011) 1.64
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2009) 1.59
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One (2011) 1.57
Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival. Cancer Epidemiol (2015) 1.56
A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res (2011) 1.55
Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res (2013) 1.54
Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One (2010) 1.54
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer (2009) 1.54
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med (2015) 1.50
Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet (2015) 1.47
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer (2013) 1.47
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". PLoS Genet (2010) 1.47
Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nat Genet (2017) 1.44
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Hum Mol Genet (2009) 1.42
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell (2010) 1.42
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer (2008) 1.38
Recreational physical activity and epithelial ovarian cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev (2007) 1.36
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res (2012) 1.35
Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol Biomarkers Prev (2007) 1.34
Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev (2009) 1.29
11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat (2012) 1.26
Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A (2013) 1.22
Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2014) 1.22
RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. J Pathol (2013) 1.20
Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS One (2011) 1.20
Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br J Cancer (2009) 1.19
Loss of lifestyle: health behaviour and weight changes after becoming a caregiver of a family member diagnosed with ovarian cancer. Support Care Cancer (2010) 1.18
Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer (2011) 1.17
Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res (Phila) (2013) 1.17
Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.14
Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol (2013) 1.10
Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer (2008) 1.10
Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer (2009) 1.08
Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum Mol Genet (2014) 1.05
Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control (2013) 1.03
Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.02
Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res (2014) 1.01
Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer (2008) 1.01
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. Hum Mol Genet (2013) 1.00
Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations. Clin Cancer Res (2012) 0.99
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet (2013) 0.99
Ovarian cancer risk associated with inherited inflammation-related variants. Cancer Res (2012) 0.98
Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS One (2011) 0.96
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer (2014) 0.96
9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev (2012) 0.95
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet (2016) 0.95
Gynecological conditions and the risk of endometrial cancer. Gynecol Oncol (2011) 0.95
Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium. Int J Cancer (2011) 0.95
The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysis. Breast Cancer Res Treat (2008) 0.95
Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer (2015) 0.95
Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers. Med J Aust (2010) 0.92
Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev (2010) 0.92
No evidence for an association between the earwax-associated polymorphism in ABCC11 and breast cancer risk in Caucasian women. Breast Cancer Res Treat (2010) 0.92
Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol (2007) 0.92
ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst (2014) 0.91
Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget (2016) 0.90
Estimating single nucleotide polymorphism associations using pedigree data: applications to breast cancer. Br J Cancer (2013) 0.90
Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiol Biomarkers Prev (2008) 0.89
Pathways to the diagnosis of epithelial ovarian cancer in Australia. Med J Aust (2010) 0.89
History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes Control (2017) 0.88